Galectin-3 is elevated in CSF and is associated with Aβ deposits and tau aggregates in brain tissue in Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
Galectin-3 (Gal-3) is a beta-galactosidase binding protein involved in microglial activation in the central nervous system (CNS). We previously demonstrated the crucial deleterious role of Gal-3 in microglial activation in Alzheimer’s disease (AD). Under AD conditions, Gal-3 is primarily expressed by microglial cells clustered around Aβ plaques in both human and mouse brain, and knocking out Gal-3 reduces AD pathology in AD-model mice. To further unravel the importance of Gal-3-associated inflammation in AD, we aimed to investigate the Gal-3 inflammatory response in the AD continuum. First, we measured Gal-3 levels in neocortical and hippocampal tissue from early-onset AD patients, including genetic and sporadic cases. We found that Gal-3 levels were significantly higher in both cortex and hippocampus in AD subjects. Immunohistochemistry revealed that Gal-3+ microglial cells were associated with amyloid plaques of a larger size and more irregular shape and with neurons containing tau-inclusions. We then analyzed the levels of Gal-3 in cerebrospinal fluid (CSF) from AD patients ( n = 119) compared to control individuals ( n = 36). CSF Gal-3 levels were elevated in AD patients compared to controls and more strongly correlated with tau (p-Tau181 and t-tau) and synaptic markers (GAP-43 and neurogranin) than with amyloid-β. Lastly, principal component analysis (PCA) of AD biomarkers revealed that CSF Gal-3 clustered and associated with other CSF neuroinflammatory markers, including sTREM-2, GFAP, and YKL-40. This neuroinflammatory component was more highly expressed in the CSF from amyloid-β positive (A+), CSF p-Tau181 positive (T+), and biomarker neurodegeneration positive/negative (N+/−) (A + T + N+/−) groups compared to the A + T−N− group. Overall, Gal-3 stands out as a key pathological biomarker of AD pathology that is measurable in CSF and, therefore, a potential target for disease-modifying therapies involving the neuroinflammatory response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




![Fig. 5 CSF Gal-3 levels are increased in AD patients and correlate with other CSF neuroinflammatory biomarkers. a CSF Gal-3 levels were measured by ELISA in control subjects and AD patients. Gal-3 levels were significantly elevated in AD patients compared to controls (*P = 0.030) after adjustment on age, sex and ApoE4 carriership. b CSF sTREM-2 levels were measured in our cohort. No difference was found between the AD and control groups in our analysis adjusted for age, sex and ApoE4 carriership (P = 0.217). c, d Analysis of ROC curves revealed moderate performance of CSF Gal-3 and sTREM-2 levels for differentiating AD patients from neurological controls (c Gal-3 AUROC = 0.80 [95% CI = 0.72–0.88], sTREM-2 AUROC = 0.78 [95% CI = 0.69–0.88]; d Gal-3 AUPRC = 0.92, sTREM-2 AUPRC = 0.91). For comparison, CSF markers p-tau and t-tau demonstrated high discriminating performance between AD and controls (c: p-tau AUROC = 0.95 [95% CI = 0.91–1.00], t-tau AUROC = 0.92 [95% CI = 0.86–0.98]; 5d: p-tau AUPRC = 1.00, t-tau AUPRC = 0.99). e, f, g The relationships between CSF Gal-3 and other CSF neuroinflammatory biomarkers—sTREM-2, GFAP and YKL-40—were studied using Spearman’s rank correlation in the whole cohort as well as in AD and neurological control (NC) subgroups](https://figures.cochat.ai/paper-figures/fd6f445758894d55a05f64ee203dc3c3/galectin-3-is-elevated-in-csf-and-is-associated-with-a-deposits-and-tau-figure-5.jpg)
![Fig. 6 CSF Gal-3 levels correlate with CSF tau and synaptic markers. a–o Scatter plots depicting the association between CSF Gal-3 levels with other CSF AD and synaptic markers in the whole cohort and in the sub-groups (neurological controls [NC] n = 36 and AD n = 119). a–c CSF Aβ ratio weakly correlated with CSF Gal-3 in the whole cohort and sub-groups. d–i CSF Gal-3 significantly correlated with CSF p-tau181 and t-tau in the whole cohort and some sub-groups. j–o CSF Gal-3 levels correlated with CSF synaptic markers neurogranin j–l and GAP-43 m–o in the whole cohort and in the AD patient sub-group. Associations were assessed using Spearman’s rank correlation. Solid line indicates regression line, and dotted lines border the 95% confidence interval](https://figures.cochat.ai/paper-figures/dea1229b8bbd4c60b9d757f72eba6983/galectin-3-is-elevated-in-csf-and-is-associated-with-a-deposits-and-tau-figure-6.jpg)
![Fig. 7 CSF Gal-3 clusters with a neuroinflammatory component in principal component analysis. a, b Principal component analysis (PCA) in the whole cohort revealed clustering of the CSF biomarkers in two principal components (a loading values of each CSF biomarker, eigenvalues, and variance explained for each component identified; b: scree-plot in Varimax rotation). Component 1 is associated with CSF core AD biomarkers (Aß ratio, p-Tau181, and t-tau) and CSF synaptic markers (neurogranin, GAP-43). Component 2 included the CSF neuroinflammation markers (Gal-3, sTREM-2, GFAP, and YKL-40). Component 1 and Component 2 accounted for 57% and 14% of the variance. c–e Identified components were compared between groups using one-way ANCOVA-adjusted on age and sex followed by post hoc Least square test, adjusted with Bonferroni for multiple comparisons. c Core AD Component 1 was significantly higher in AD patients than in all other groups (****P < 0.0001 versus all other groups). d Neuroinflammation Component 2 did not differ between the groups. e Focusing on the patients on the AD continuum, neuroinflammatory Component 2 was significantly higher in patients with a [A + T + N +] CSF profile compared to patients with an [A + T−N−] profile (P = 0.002)](https://figures.cochat.ai/paper-figures/317c064a02154400aeb3b50772fc26a2/galectin-3-is-elevated-in-csf-and-is-associated-with-a-deposits-and-tau-figure-7.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In both AD patients and Aβ amyloidosis model mice, Gal-3 is significantly elevated in microglia clustered around Aβ plaques, where it induces neuroinflammation and neurodegeneration17,18.”
From Deletion of SPI1 in microglia exacerbates amyloid pathology by impairing microglial response in Alzheimer’s disease models (2026) · cites this paper as [18]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537 · cited 2×
“AD diagnosis was made according to the NIAAAA’s most recent diagnostic research criteria [25].”
Self-citationA Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.018 · Cited by 5,493 · cited 3×
“Brain expression of TREM-2 has also been linked to disease-associated microglial phenotype and plaque growth dynamics [29, 32, 54, 61].”
Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent Manner
Schafer, D. P., Lehrman, E. K., Kautzman, A. G., Koyama, R., Mardinly, A. R., Yamasaki, R., Ransohoff, R. M., Greenberg, M. E., Barres, B. A., & Stevens, B. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.026 · Cited by 4,089 · cited 1×
“In AD, microglia constitute a cellular mediator of synapse loss through phagocytosis or release of synaptotoxic factors [9, 22, 36, 45].”
Complement and microglia mediate early synapse loss in Alzheimer mouse models
Hong, S., Beja-Glasser, V. F., Nfonoyim, B. M., Frouin, A., Li, S., Ramakrishnan, S., Merry, K. M., Shi, Q., Rosenthal, A., Barres, B. A., et al. (2016) · Science · doi:10.1126/science.aad8373 · Cited by 3,343 · cited 2×
“Synaptic dysfunction is an early feature in AD, and recent studies suggest that microglia-mediated synapse removal could be a contributing factor [22].”
Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
Leng, F., & Edison, P. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00435-y · Cited by 3,179 · cited 1×
“This quadratic relation might reflect the evolution of microglial activation over different stages of the pathology [33, 37].”
Krasemann, S., Madore, C., Cialic, R., Baufeld, C., Calcagno, N., El Fatimy, R., Beckers, L., O’Loughlin, E., Xu, Y., Fanek, Z., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.08.008 · Cited by 2,979 · cited 5×
“[30], depends on TREM-2-ApoE signaling, shares similarities with the DAM phenotype, and involves key genes such as Gal-3, Clec7a, Itgax and Spp1.”
InfluentialA/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Feldman, H. H., Frisoni, G. B., Hampel, H., Jagust, W. J., Johnson, K. A., Knopman, D. S., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002923 · Cited by 1,864 · cited 1×
“CSF profile was classified according to the ATN classification: A+/− indicating biomarker evidence of Aβ deposition; T ± indicating biomarker evidence of pathologic tau; and N+/− indicating biomarker evidence of neurodegeneration [26].”
Self-citationTREM2 Maintains Microglial Metabolic Fitness in Alzheimer’s Disease
Ulland, T. K., Song, W. M., Huang, S. C.-C., Ulrich, J. D., Sergushichev, A., Beatty, W. L., Loboda, A. A., Zhou, Y., Cairns, N. J., Kambal, A., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.023 · Cited by 1,263 · cited 1×
“Brain expression of TREM-2 has also been linked to disease-associated microglial phenotype and plaque growth dynamics [29, 32, 54, 61].”
Clinical diagnosis of Alzheimer’s disease: Recommendations of the International Working Group
Dubois, B., Villain, N., Frisoni, G. B., Rabinovici, G. D., Sabbagh, M., Cappa, S., Bejanin, A., Bombois, S., Epelbaum, S., Teichmann, M., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00066-1 · Cited by 1,051 · cited 2×
“Traditionally, Aβ, p-Tau and tau are the main diagnostic biomarkers for AD used in clinical practice [16].”
Self-citationMicroglial signatures and their role in health and disease
Butovsky, O., & Weiner, H. L. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0057-5 · Cited by 1,046 · cited 1×
“They play diverse roles, including brain parenchyma surveillance, phagocytosis, synaptic remodeling, and inflammatory response [11].”
Wightman, D. P., Jansen, I. E., Savage, J. E., Shadrin, A. A., Bahrami, S., Holland, D., Rongve, A., Børte, S., Winsvold, B. S., Drange, O. K., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00921-z · Cited by 1,011 · cited 1×
“Genome-wide association studies have also identified innate immunity-related variants in genes such as TREM-2, CD33, CR1 and MEF2C [14, 15, 20, 56] that are associated with a significant risk of developing AD.”
Self-citationAlzheimer’s Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta
Griciuc, A., Serrano-Pozo, A., Parrado, A. R., Lesinski, A. N., Asselin, C. N., Mullin, K., Hooli, B., Choi, S. H., Hyman, B. T., & Tanzi, R. E. (2013) · Neuron · doi:10.1016/j.neuron.2013.04.014 · Cited by 1,004
Johnson, E. C. B., Dammer, E. B., Duong, D. M., Ping, L., Zhou, M., Yin, L., Higginbotham, L. A., Guajardo, A., White, B., Troncoso, J. C., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0815-6 · Cited by 1,001 · cited 3×
“An astrocytic/microglial metabolism module was significantly enriched in gene products connected to AD risk factor loci [28].”
Microglial Phagocytosis of Live Neurons
Brown, G. C., & Neher, J. J. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3710 · Cited by 853 · cited 1×
“In AD, microglia constitute a cellular mediator of synapse loss through phagocytosis or release of synaptotoxic factors [9, 22, 36, 45].”
Yuan, P., Condello, C., Keene, C. D., Wang, Y., Bird, T. D., Paul, S. M., Luo, W., Colonna, M., Baddeley, D., & Grutzendler, J. (2016) · Neuron · doi:10.1016/j.neuron.2016.05.003 · Cited by 817
Benedet, A. L., Milà-Alomà, M., Vrillon, A., Ashton, N. J., Pascoal, T. A., Lussier, F., Karikari, T. K., Hourregue, C., Cognat, E., Dumurgier, J., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.3671 · Cited by 638 · cited 1×
“Like YKL-40, GFAP has been linked to astrocyte activity and found to be consistently elevated in CSF and serum of patients in preclinical and symptomatic AD stages [6, 24, 39].”
Self-citationMicroglial Remodeling of the Extracellular Matrix Promotes Synapse Plasticity
Nguyen, P. T., Dorman, L. C., Pan, S., Vainchtein, I. D., Han, R. T., Nakao-Inoue, H., Taloma, S. E., Barron, J. J., Molofsky, A. B., Kheirbek, M. A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.050 · Cited by 615 · cited 2×
“In AD, microglia constitute a cellular mediator of synapse loss through phagocytosis or release of synaptotoxic factors [9, 22, 36, 45].”
LRP1 is a master regulator of tau uptake and spread
Rauch, J. N., Luna, G., Guzman, E., Audouard, M., Challis, C., Sibih, Y. E., Leshuk, C., Hernandez, I., Wegmann, S., Hyman, B. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2156-5 · Cited by 541
Suárez‐Calvet, M., Kleinberger, G., Araque Caballero, M. Á., Brendel, M., Rominger, A., Alcolea, D., Fortea, J., Lleó, A., Blesa, R., Gispert, J. D., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201506123 · Cited by 522
Self-citationMicroglial activation and tau propagate jointly across Braak stages
Pascoal, T. A., Benedet, A. L., Ashton, N. J., Kang, M. S., Therriault, J., Chamoun, M., Savard, M., Lussier, F. Z., Tissot, C., Karikari, T. K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01456-w · Cited by 490 · cited 3×
“Indeed, this study revealed that tau propagation is more dependent on microglial networks than tau network circuits [40].”
InfluentialSelf-citationMicroglia use TAM receptors to detect and engulf amyloid β plaques
Huang, Y., Happonen, K. E., Burrola, P. G., O’Connor, C., Hah, N., Huang, L., Nimmerjahn, A., & Lemke, G. (2021) · Nature Immunology · doi:10.1038/s41590-021-00913-5 · Cited by 483 · cited 2×
“Recently, the importance of two specific TAM receptors, Axl and MerTK, has been highlighted in the detection and engulfment of Aβ plaques [23].”
Lee, C. Y. D., Daggett, A., Gu, X., Jiang, L.-L., Langfelder, P., Li, X., Wang, N., Zhao, Y., Park, C. S., Cooper, Y., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.02.002 · Cited by 396 · cited 1×
“Brain expression of TREM-2 has also been linked to disease-associated microglial phenotype and plaque growth dynamics [29, 32, 54, 61].”
Burguillos, M. A., Svensson, M., Schulte, T., Boza-Serrano, A., Garcia-Quintanilla, A., Kavanagh, E., Santiago, M., Viceconte, N., Oliva-Martin, M. J., Osman, A. M., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.02.012 · Cited by 365 · cited 3×
“Because of this, Gal-3 can be detected in CSF and serum [3, 8, 10, 55, 59].”
Self-citationBoza-Serrano, A., Ruiz, R., Sanchez-Varo, R., García-Revilla, J., Yang, Y., Jimenez-Ferrer, I., Paulus, A., Wennström, M., Vilalta, A., Allendorf, D., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02013-z · Cited by 357 · cited 6×
“We demonstrated a subpopulation of microglia clustered around Aβ plaques identified by high expression of Gal-3[8].”
InfluentialSelf-citationInitiative, F. T. A. D. N., Suárez-Calvet, M., Morenas-Rodríguez, E., Kleinberger, G., Schlepckow, K., Araque Caballero, M. Á., Franzmeier, N., Capell, A., Fellerer, K., Nuscher, B., et al. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0301-5 · Cited by 347 · cited 1×
“A key microglial marker, TREM-2, has also been noted as being elevated in AD patient CSF [18, 51] and has recently been linked to slower Aβ deposition [17], reduced cognitive decline [18] and taurelated neurodegeneration [52].”
Oeckl, P., Halbgebauer, S., Anderl-Straub, S., Steinacker, P., Huss, A. M., Neugebauer, H., von Arnim, C. A. F., Diehl-Schmid, J., Grimmer, T., Kornhuber, J., et al. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-180325 · Cited by 345 · cited 1×
“Like YKL-40, GFAP has been linked to astrocyte activity and found to be consistently elevated in CSF and serum of patients in preclinical and symptomatic AD stages [6, 24, 39].”
Ewers, M., Franzmeier, N., Suárez-Calvet, M., Morenas-Rodriguez, E., Caballero, M. A. A., Kleinberger, G., Piccio, L., Cruchaga, C., Deming, Y., Dichgans, M., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav6221 · Cited by 327 · cited 3×
“It is important to note that these studies were longitudinal studies on genetic-case cohorts (DIAN) or studies focused on the early stages of AD pathology [17, 18, 50, 51].”
Cuyvers, E., & Sleegers, K. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00127-7 · Cited by 284 · cited 1×
“Genome-wide association studies have also identified innate immunity-related variants in genes such as TREM-2, CD33, CR1 and MEF2C [14, 15, 20, 56] that are associated with a significant risk of developing AD.”
Clearance of cerebral Aβ in Alzheimer’s disease: reassessing the role of microglia and monocytes
Zuroff, L., Daley, D., Black, K. L., & Koronyo-Hamaoui, M. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2463-7 · Cited by 275
Glial activation and inflammation along the Alzheimer’s disease continuum
Nordengen, K., Kirsebom, B.-E., Henjum, K., Selnes, P., Gísladóttir, B., Wettergreen, M., Torsetnes, S. B., Grøntvedt, G. R., Waterloo, K. K., Aarsland, D., et al. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1399-2 · Cited by 274 · cited 2×
“This quadratic relation might reflect the evolution of microglial activation over different stages of the pathology [33, 37].”
Suárez-Calvet, M., Araque Caballero, M. Á., Kleinberger, G., Bateman, R. J., Fagan, A. M., Morris, J. C., Levin, J., Danek, A., Ewers, M., Haass, C., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aag1767 · Cited by 272 · cited 1×
“It is important to note that these studies were longitudinal studies on genetic-case cohorts (DIAN) or studies focused on the early stages of AD pathology [17, 18, 50, 51].”
Deczkowska, A., Matcovitch-Natan, O., Tsitsou-Kampeli, A., Ben-Hamo, S., Dvir-Szternfeld, R., Spinrad, A., Singer, O., David, E., Winter, D. R., Smith, L. K., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00769-0 · Cited by 260 · cited 1×
“Genome-wide association studies have also identified innate immunity-related variants in genes such as TREM-2, CD33, CR1 and MEF2C [14, 15, 20, 56] that are associated with a significant risk of developing AD.”
YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias
Llorens, F., Thüne, K., Tahir, W., Kanata, E., Diaz-Lucena, D., Xanthopoulos, K., Kovatsi, E., Pleschka, C., Garcia-Esparcia, P., Schmitz, M., et al. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0226-4 · Cited by 249 · cited 1×
“In AD, YKL-40 has been found to be elevated and associated with astrocyte reactivity [31, 34, 42].”
Self-citationImmune hyperreactivity of Aβ plaque-associated microglia in Alzheimer's disease
Yin, Z., Raj, D., Saiepour, N., Van Dam, D., Brouwer, N., Holtman, I. R., Eggen, B. J. L., Möller, T., Tamm, J. A., Abdourahman, A., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.03.021 · Cited by 238
Schöll, M., Maass, A., Mattsson, N., Ashton, N. J., Blennow, K., Zetterberg, H., & Jagust, W. (2019) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2018.12.001 · Cited by 229 · cited 1×
“Cerebrospinal fluid (CSF) plays a key role in brain metabolism and can be used to measure the concentration of pathological hallmarks related to AD pathology progression [4, 25, 46].”
Self-citationTau activates microglia via the PQBP1-cGAS-STING pathway to promote brain inflammation
Jin, M., Shiwaku, H., Tanaka, H., Obita, T., Ohuchi, S., Yoshioka, Y., Jin, X., Kondo, K., Fujita, K., Homma, H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26851-2 · Cited by 223 · cited 1×
“This microglial inflammatory response is dependent on NFκB-dependent transcription of inflammatory genes, leading to brain inflammation [27].”
Galectin-3 as a Next-Generation Biomarker for Detecting Early Stage of Various Diseases
Hara, A., Niwa, M., Noguchi, K., Kanayama, T., Niwa, A., Matsuo, M., Hatano, Y., & Tomita, H. (2020) · Biomolecules · doi:10.3390/biom10030389 · Cited by 214 · cited 1×
“Interestingly, Gal-3 has been detected in the CSF of AD patients and its measures suggest that it could be elevated in AD [21, 59].”
Lananna, B. V., McKee, C. A., King, M. W., Del-Aguila, J. L., Dimitry, J. M., Farias, F. H. G., Nadarajah, C. J., Xiong, D. D., Guo, C., Cammack, A. J., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax3519 · Cited by 201 · cited 1×
“In AD, YKL-40 has been found to be elevated and associated with astrocyte reactivity [31, 34, 42].”
Microglial activation and tau burden predict cognitive decline in Alzheimer’s disease
Malpetti, M., Kievit, R. A., Passamonti, L., Jones, P. S., Tsvetanov, K. A., Rittman, T., Mak, E., Nicastro, N., Bevan-Jones, W. R., Su, L., et al. (2020) · Brain · doi:10.1093/brain/awaa088 · Cited by 194 · cited 1×
“Indeed, the combination of neuroinflammatory microglial activity and tau deposition measured by PET predicts cognitive decline in AD [35].”
Elevated CSF GAP‐43 is Alzheimer's disease specific and associated with tau and amyloid pathology
Sandelius, Å., Portelius, E., Källén, Å., Zetterberg, H., Rot, U., Olsson, B., Toledo, J. B., Shaw, L. M., Lee, V. M. Y., Irwin, D. J., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.08.006 · Cited by 189 · cited 1×
“In our work, CSF Gal-3 correlated with pre-synaptic protein GAP-43, which displays a significant increase in AD and correlates with the magnitude of neurofibrillary tangles and Aβ plaques [44].”
Self-citationGaetani, L., Höglund, K., Parnetti, L., Pujol-Calderon, F., Becker, B., Eusebi, P., Sarchielli, P., Calabresi, P., Di Filippo, M., Zetterberg, H., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0339-1 · Cited by 178 · cited 1×
“CSF neurofilament light (NfL) was measured using an in-house sandwich ELISA with capture and detection antibodies directed against the central rod domain of the protein, NfL21 and NfL23, respectively, as described previously [19].”
Self-citationGalectin-3 is a new MerTK-specific eat-me signal
Caberoy, N. B., Alvarado, G., Bigcas, J., & Li, W. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.22955 · Cited by 176 · cited 1×
“Therefore, the Aβ inclusion observed inside microglial cells expressing Gal-3 may be partially mediated by Axl, MerTK and Gal-3 interaction [12].”
Shahidehpour, R. K., Higdon, R. E., Crawford, N. G., Neltner, J. H., Ighodaro, E. T., Patel, E., Price, D., Nelson, P. T., & Bachstetter, A. D. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.12.003 · Cited by 173 · cited 1×
“This may indicate that in the latest stage of AD pathology, microglial cells become dystrophic [47, 49] with impaired functionality, activation capacity and Gal-3 production and release.”
Portelius, E., Olsson, B., Höglund, K., Cullen, N. C., Kvartsberg, H., Andreasson, U., Zetterberg, H., Sandelius, Å., Shaw, L. M., Lee, V. M. Y., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1851-x · Cited by 169 · cited 2×
“CSF Gal-3 also correlates with levels of neurogranin, a postsynaptic protein consistently increased in CSF in AD [41].”
Self-citationQuerol-Vilaseca, M., Colom-Cadena, M., Pegueroles, J., San Martín-Paniello, C., Clarimon, J., Belbin, O., Fortea, J., & Lleó, A. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0893-7 · Cited by 158 · cited 1×
“In AD, YKL-40 has been found to be elevated and associated with astrocyte reactivity [31, 34, 42].”
Ishiki, A., Kamada, M., Kawamura, Y., Terao, C., Shimoda, F., Tomita, N., Arai, H., & Furukawa, K. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13399 · Cited by 156 · cited 2×
“Like YKL-40, GFAP has been linked to astrocyte activity and found to be consistently elevated in CSF and serum of patients in preclinical and symptomatic AD stages [6, 24, 39].”
Dystrophic microglia in late‐onset Alzheimer's disease
Streit, W. J., Khoshbouei, H., & Bechmann, I. (2020) · Glia · doi:10.1002/glia.23782 · Cited by 152 · cited 1×
“This may indicate that in the latest stage of AD pathology, microglial cells become dystrophic [47, 49] with impaired functionality, activation capacity and Gal-3 production and release.”
Yasuno, F., Kosaka, J., Ota, M., Higuchi, M., Ito, H., Fujimura, Y., Nozaki, S., Takahashi, S., Mizukami, K., Asada, T., et al. (2012) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2011.08.013 · Cited by 148
Cerebrospinal Fluid Level of YKL-40 Protein in Preclinical and Prodromal Alzheimer's Disease
Antonell, A., Mansilla, A., Rami, L., Lladó, A., Iranzo, A., Olives, J., Balasa, M., Sánchez-Valle, R., & Molinuevo, J. L. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-140624 · Cited by 139 · cited 7×
“A specific AD microglial phenotype was recently discovered, the socalled disease-associated microglia (DAM) [2].”
InfluentialSelf-citationGalectin-3 promotes Aβ oligomerization and Aβ toxicity in a mouse model of Alzheimer’s disease
Tao, C.-C., Cheng, K.-M., Ma, Y.-L., Hsu, W.-L., Chen, Y.-C., Fuh, J.-L., Lee, W.-J., Chao, C.-C., & Lee, E. H. Y. (2020) · Cell Death & Differentiation · doi:10.1038/s41418-019-0348-z · Cited by 138
Ewers, M., Biechele, G., Suárez‐Calvet, M., Sacher, C., Blume, T., Morenas‐Rodriguez, E., Deming, Y., Piccio, L., Cruchaga, C., Kleinberger, G., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012308 · Cited by 133 · cited 3×
“It is important to note that these studies were longitudinal studies on genetic-case cohorts (DIAN) or studies focused on the early stages of AD pathology [17, 18, 50, 51].”
LRP1 modulates the microglial immune response via regulation of JNK and NF‐ΚB signaling pathways
Yang, L., Liu, C.-C., Zheng, H., Kanekiyo, T., Atagi, Y., Jia, L., Wang, D., N’songo, A., Can, D., Xu, H., et al. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0772-7 · Cited by 129
Astrocyte Biomarkers in Alzheimer Disease: A Systematic Review and Meta-analysis
Bellaver, B., Ferrari-Souza, J. P., Uglione da Ros, L., Carter, S. F., Rodriguez-Vieitez, E., Nordberg, A., Pellerin, L., Rosa-Neto, P., Leffa, D. T., & Zimmer, E. R. (2021) · Neurology · doi:10.1212/wnl.0000000000012109 · Cited by 123
Alosco, M. L., Tripodis, Y., Fritts, N. G., Heslegrave, A., Baugh, C. M., Conneely, S., Mariani, M., Martin, B. M., Frank, S., Mez, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.05.004 · Cited by 121
Self-citationHara, A., Niwa, M., Kanayama, T., Noguchi, K., Niwa, A., Matsuo, M., Kuroda, T., Hatano, Y., Okada, H., & Tomita, H. (2020) · Biomolecules · doi:10.3390/biom10091277 · Cited by 116
Elevated Galectin-3 Levels in the Serum of Patients With Alzheimer's Disease
Wang, X., Zhang, S., Lin, F., Chu, W., & Yue, S. (2015) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/1533317513495107 · Cited by 100 · cited 1×
“Because of this, Gal-3 can be detected in CSF and serum [3, 8, 10, 55, 59].”
The pleiotropic effects of galectin-3 in neuroinflammation: A review
Shin, T. (2013) · Acta Histochemica · doi:10.1016/j.acthis.2012.11.010 · Cited by 98 · cited 1×
“Gal-3 consists of one N-terminal domain and one carbohydrate recognition domain [48] and is released into the extracellular space by activated microglia.”
The coarse-grained plaque: a divergent Aβ plaque-type in early-onset Alzheimer’s disease
Boon, B. D. C., Bulk, M., Jonker, A. J., Morrema, T. H. J., van den Berg, E., Popovic, M., Walter, J., Kumar, S., van der Lee, S. J., Holstege, H., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02198-8 · Cited by 93
Update on Biomarkers For Amyloid Pathology in Alzheimer’s Disease
Ashton, N. J., Schöll, M., Heurling, K., Gkanatsiou, E., Portelius, E., Höglund, K., Brinkmalm, G., Hye, A., Blennow, K., & Zetterberg, H. (2018) · Biomarkers in Medicine · doi:10.2217/bmm-2017-0433 · Cited by 75 · cited 2×
“As the AD process initiates, CSF Aβ42 levels drop and the levels of different isoforms of tau increase, which is associated with neurodegeneration [4].”
Self-citationIncreased tauopathy drives microglia-mediated clearance of beta-amyloid
Chen, W., Abud, E. A., Yeung, S. T., Lakatos, A., Nassi, T., Wang, J., Blum, D., Buée, L., Poon, W. W., & Blurton-Jones, M. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0336-1 · Cited by 52 · cited 1×
“3a–g), which may indicate plaque phagocytosis by the microglia [13, 23, 60, 62].”
Ashraf, G. M., & Baeesa, S. S. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00430 · Cited by 48 · cited 1×
“Because of this, Gal-3 can be detected in CSF and serum [3, 8, 10, 55, 59].”
Obermann, J., Priglinger, C. S., Merl-Pham, J., Geerlof, A., Priglinger, S., Götz, M., & Hauck, S. M. (2017) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m116.066381 · Cited by 44 · cited 2×
“A key regulator of tau propagation is Low-Density Lipoprotein 1 receptor (LRP1), which has been related to tau uptake and spreading [43] and also to the microglial inflammatory response [57].”
Evaluation of serum galectin-3 levels at Alzheimer patients by stages: a preliminary report
Yazar, T., Yazar, H. O., & Cihan, M. (2020) · Acta Neurologica Belgica · doi:10.1007/s13760-020-01477-1 · Cited by 41 · cited 2×
“Because of this, Gal-3 can be detected in CSF and serum [3, 8, 10, 55, 59].”
Cited by
Targeting galectin-3 in inflammatory and fibrotic diseases
Bouffette, S., Botez, I., & De Ceuninck, F. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.06.001 · Cited by 165
Microglia dynamics in aging-related neurobehavioral and neuroinflammatory diseases
Javanmehr, N., Saleki, K., Alijanizadeh, P., & Rezaei, N. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02637-1 · Cited by 119
Noh, M., Kwon, H. S., Kwon, M., Nahm, M., Jin, H. K., Bae, J., & Kim, S. H. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00867-4 · Cited by 97
Melchiorri, D., Merlo, S., Micallef, B., Borg, J.-J., & Dráfi, F. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1196413 · Cited by 70
“, 2019), and galectin-3 levels in blood or CSF were shown to be elevated in AD patients (Wang X. et al., 2015; Yazar et al., 2021; Boza-Serrano et al., 2022).”
BackgroundBiomarkers in Alzheimer’s disease
Rajendran, K., & Krishnan, U. M. (2024) · Clinica Chimica Acta · doi:10.1016/j.cca.2024.119857 · Cited by 58
Metadata
- Authors
- Boza-Serrano, A., Vrillon, A., Minta, K., Paulus, A., Camprubí-Ferrer, L., Garcia, M., Andreasson, U., Antonell, A., Wennström, M., Gouras, G., Dumurgier, J., Cognat, E., Molina-Porcel, L., Balasa, M., Vitorica, J., Sánchez-Valle, R., Paquet, C., Venero, J. L., Blennow, K., & Deierborg, T.
- Affiliations
- Inserm (FR)
- University of Gothenburg (SE)
- Lund University (SE)
- Hospital Clínic de Barcelona (ES)
- Instituto de Biomedicina de Sevilla (ES)
- Sahlgrenska University Hospital (SE)
- Corresponding author
- Vrillon, Agathe
- ORCID
- Venue
- Acta Neuropathologica
- Published
- 2022-07-27
- Volume
- 144
- Issue
- 5
- Pages
- 843-859
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- PMC
- PMC9547798
- OpenAlex
- W4288177782
- Cited by
- 66
- References
- 63
- Citations by year
- 2026: 15 · 2025: 20 · 2024: 16 · 2023: 12 · 2022: 3
- FWCI
- 7.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Acta Neuropathologica (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by)
- Deposito de Investigacion Universidad de Sevilla (University of Seville) (submittedVersion, cc-by)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, cc-by)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion, cc-by)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- Vetenskapsrådet (2019-0633)
- Ministerio de Ciencia, Innovación y Universidades (RTI2018-098645-B-100, PID2021-124096OB-100)
- Instituto de Salud Carlos III (20/00448, Union PI18/01556, PI21/00914)
- Consejería de Economía, Innovación, Ciencia y Empleo, Junta de Andalucía (P18-RT-1372, US-1262734)
- Kungliga Fysiografiska Sällskapet i Lund (20191114ABS, 20211129ABS)
- Greta och Johan Kocks stiftelser (20201201ABS)
- Consejería de Economía, Conocimiento, Empresas y Universidad, Junta de Andalucía (US-1264806)
- Lund University
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- galectin-3, Alzheimer's disease, cerebrospinal fluid biomarkers, amyloid plaques, tau inclusions, neuroinflammation, microglial activation, p-tau181, neurogranin, GAP-43, glial fibrillary acidic protein, YKL-40, hippocampus, neocortex, early-onset Alzheimer's disease, disease-modifying therapy
- MeSH terms
- Chitinase-3-Like Protein 1, Alzheimer Disease, Animals, beta-Galactosidase, Brain, Humans, Biomarkers, Amyloid beta-Peptides, tau Proteins, GAP-43 Protein, Galectin 3, Mice, Neurogranin, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.